The Biden-Harris Administration has proposed expanding Medicare and Medicaid coverage for anti-obesity medications, aiming to address the high costs that have drawn criticism. In the U.S., Novo Nordisk A/S (NYSE:NVO) has faced backlash for the steep prices of Wegovy and Ozempic, two popular drugs in this category.
While Novo Nordisk’s CEO Lars Fruergaard Jørgensen has defended the high U.S. prices of the company’s blockbuster drugs, Ozempic and Wegovy, stating that these medications are reducing the economic burden of obesity-related health issues.
